CompletedPhase 4

Salivary Drug Concentration Exploratory Study of Cetylpyridinium Chloride Buccal Tablets

China10 participantsStarted 2023-04-10

Plain-language summary

The study is a single-arm, open-label study to explore the salivary concentration of Cetylpyridinium Chloride Buccal Tablets after single-dose administration in Healthy Subjects

Who can participate

Age range18 Years – 45 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subjects who have fully understand the objective, character, methods and potential adverse reactions of the trial, voluntarily participate in the study, and sign the informed consent form before enrolled into the study.
✓. Healthy subjects aged 18-45 (both inclusive) with an appropriate ratio of male to female.
✓. Subjects who had no parenthood plan from the signing of the informed consent form to one month after completing study, and agreed to take effective and appropriate contraceptive measures voluntarily by themselves and their partners during this period.
✓. Subjects those who be able to communicate well with investigators, and be able to understand and comply with the requirements of this study.

Exclusion criteria

✕. Allergic to any ingredients of this product or excipients (sucrose, Hypromellose, Carbomer 934P, Tartrazine aluminium lake, menthol,Magnesium octadecanoate, Povidone K 30)
✕. Pregnant or breastfeeding women
✕. Participants with abnormal salivary secretion, such as patients with xerostomia and diabetic dry mouth
✕. Usage of oral stimulants, salivary gland stimulants, other treatments or saliva substitute treatment that may affect salivary gland secretion within 7 days before screening
✕. Those who cannot tolerate venipuncture or have a history of haemorrhage or needle fainting
✕. Those who on special diet, who cannot comply with the standard diet of the study center, who have difficulty swallowing, who are lactose intolerant, or who have galactosemia or glucose/galactose absorption disorders
✕. Those who indicated as abnormal with clinical significance in screening laboratory examination, physical examination, vital signs or electrocardiogram inspection based on judgement of clinical study doctor.
✕. The subjects may not be able to complete the study following protocol due to other reasons or investigators judge that they are not suitable participants.

What they're measuring

Salivary plasma drug concentration

Timeframe: 15 minutes, 0.5 hour, 1 hour, 1.5 hours, 2 hours after dosing

Trial details

NCT IDNCT05802628

SponsorPeking University People's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-04-18

View on ClinicalTrials.gov More Pharyngitis Acute trials